Mibg (I-123)

Iobenguane I-123, the active ingredient in Mibg (I-123), is a radiopharmaceutical presented as an injectable solution for intravenous use. It is used for diagnostic imaging of certain neuroendocrine tumors and assessment of cardiac sympathetic innervation. GNH USA supplies Mibg (I-123) as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide.

Iobenguane I-123 is used in nuclear medicine imaging of adrenergic tissue‑related conditions. - Pheochromocytoma and paraganglioma: enables precise localization and staging of catecholamine‑producing tumors. - Neuroblastoma: assists in detection and assessment of disease extent in pediatric patients. - Cardiac sympathetic innervation assessment: evaluates myocardial sympathetic nerve function in heart failure or arrhythmia risk stratification.

Adverse reactions to Iobenguane I-123 are generally related to the radiopharmaceutical nature of the product and the intravenous administration.

Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Flushing: temporary reddening of skin, often at injection site. - Headache: mild to moderate discomfort following administration. - Injection site pain: brief soreness or discomfort at the IV site.

Serious or Rare Side Effects: - Allergic reaction: hives, swelling, or anaphylaxis requiring immediate medical attention. - Radiation‑induced tissue injury: rare localized damage from radiation exposure. - Severe hypotension: sudden drop in blood pressure after injection. - Thyroid dysfunction: abnormal thyroid hormone levels due to iodine exposure.

When using Iobenguane I-123, several precautions should be observed to ensure patient safety and product integrity. - Pregnancy: avoid use unless clearly needed, as fetal radiation exposure is unknown. - Breastfeeding: discontinue nursing or assess risk, because iodine may be secreted in milk. - Renal impairment: consider reduced clearance; monitor renal function. - Concomitant iodine‑containing drugs: evaluate potential interference with imaging results. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane I-123 may interact with certain substances that affect iodine handling or adrenergic pathways.

Major Interactions (Avoid): - Thyroid hormone therapy: can alter iodine distribution and affect imaging interpretation. - Sympathetic blockers (e.g., phenoxybenzamine): may reduce tracer uptake in target tissues.

Moderate Interactions (Monitor Closely): - Iodinated contrast agents: may compete for iodine uptake, potentially diminishing image quality. - Diuretics: can affect renal clearance of the radiotracer. - Antidepressants affecting norepinephrine reuptake: may modify tracer dynamics.